This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DSGX's Routing Solution Adopted by Mitchell Companies: Stock to Gain?
by Zacks Equity Research
Mitchell Companies is utilizing Descartes' route planning and execution platform to enhance distribution efficiency and maintain high delivery productivity.
Down -12.46% in 4 Weeks, Here's Why OptimizeRx (OPRX) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for OptimizeRx (OPRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
OptimizeRx Corp. (OPRX) Tops Q2 Earnings Estimates
by Zacks Equity Research
OptimizeRx (OPRX) delivered earnings and revenue surprises of 128.57% and 8.10%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
NuScale Power (SMR) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
NuScale Power's (SMR) second-quarter 2024 performance is likely to reflect strong demand for electricity powering AI-supported data centers.
DigitalOcean (DOCN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
DigitalOcean's (DOCN) second-quarter 2024 performance is likely to reflect the benefits of a robust product portfolio and the strong demand for its AI platform and cloud-based services.
Smith Micro Software, Inc. (SMSI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Smith Micro Software (SMSI) delivered earnings and revenue surprises of -8.57% and 4.82%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
OptimizeRx (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 34.8% upside potential for OptimizeRx (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Open Text (OTEX) Q3 Earnings Meet Estimates
by Zacks Equity Research
Open Text (OTEX) delivered earnings and revenue surprises of 0% and 1.36%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
by Zacks Equity Research
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
by Zacks Equity Research
OptimizeRx (OPRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 7.69% and 2.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for January 11th
by Zacks Equity Research
ADMA, ARQT, PHR, OPRX and PHG have been added to the Zacks Rank #1 (Strong Buy) List on January 11, 2024.
OptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 41.3% upside potential for OptimizeRx Corp. (OPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks.com featured highlights Freshpet, OptimizeRx and Pinterest
by Zacks Equity Research
Freshpet, OptimizeRx and Pinterest have been highlighted in this Screen of The Week article.
3 Stocks Worth a Buy for Superb Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Freshpet (FRPT), OptimizeRx (OPRX) and Pinterest (PINS) at the moment for solid earnings acceleration.
Why OptimizeRx Corp. (OPRX) Might be Well Poised for a Surge
by Zacks Equity Research
OptimizeRx Corp. (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
How Much Upside is Left in OptimizeRx Corp. (OPRX)? Wall Street Analysts Think 47.72%
by Zacks Equity Research
The mean of analysts' price targets for OptimizeRx Corp. (OPRX) points to a 47.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
OptimizeRx Corp. (OPRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OptimizeRx Corp. (OPRX) Surges 13.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -12.50% and 5.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OptimizeRx Corp. (OPRX) Soars 7.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates
by Zacks Equity Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 4.17% and 9.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Sea Limited (SE) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Sea Limited's (SE) fourth-quarter 2022 results are likely to benefit from a stable Free Fire user base and the growing popularity of Shopee.